

Dear XXXX,

NOW APPROVED: KYPROLIS®, as part of combination therapy with dexamethasone or lenalidomide and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.[1]

In the Phase 3, head-to-head study with KYPROLIS® and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) for patients with relapsed or refractory multiple myeloma (ENDEAVOR), Kd:

- **Doubled** the median **progression-free survival*** vs Vd
  (18.7 vs 9.4 months; $p<0.0001$)[1,2]
  *Primary endpoint of ENDEAVOR study. Progression-free survival was assessed by an independent review committee.[2]
- **Doubled** the number of patients achieving a **complete response** or better vs Vd
  (13% vs 6%; descriptive $p=0.001$†)[1,2]
  †Not a pre-specified secondary endpoint with statistical testing. P-value is for descriptive purposes only.
- Presented a favourable benefit–risk profile with **significantly less peripheral neuropathy** vs Vd
  (Grade ≥2‡, 6% vs 32%; $p<0.0001$)[1,2]
  ‡Analysis of Grade 2 or higher peripheral neuropathy events is based on safety population.
  79% of patients in the bortezomib group received subcutaneous bortezomib throughout study treatment.

We hope that you find these Kd vs Vd results valuable and that you will consider using the Kd regimen in multiple myeloma patients who have received one prior therapy.

Sincerely,

AMGEN®

Kyprolis® (carfilzomib)

Kd regimen: administer KYPROLIS® (56 mg/m^2) as a 30-minute IV infusion on two consecutive days each week for 3 weeks (Days 1, 2, 8, 9, 15 and 16), followed by a 12-day rest period (Days 17 to 28). Each 28-day period is considered one treatment cycle. An initial dose (20 mg/m^2) should be used for Days 1 and 2 to evaluate tolerability. Dexamethasone (20 mg) should be administered 30 minutes to 4 hours before KYPROLIS® on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Treatment may be continued until disease progression or unacceptable toxicity occurs.[1]

References: 1. KYPROLIS® (carfilzomib) Approved Product Information. Available at www.amgen.com.au/Kyprolis.PI. **2.** Dimopoulos MA *et al. Lancet Oncol* 2016;17(1):27–38.

ENDEAVOR was a randomised, Phase 3, head-to-head, open-label, multicentre study comparing KYPROLIS® + dexamethasone vs bortezomib + dexamethasone in patients with relapsed or refractory multiple myeloma (n=929). Patients received their randomised study treatment in 28-day (Kd) or 21-day (Vd) cycles until disease progression, withdrawal of consent, or unacceptable toxicity. Primary endpoint was progression-free survival. Secondary endpoints included overall survival, overall response rate, duration of response, Grade ≥2 peripheral neuropathy, and safety.[1,2]

PBS information: This product is not listed on the PBS.

Please refer to product information before prescribing.
Full product information is available at www.amgen.com.au/Kyprolis.PI